MSN Labs launches Posaconazole (PosaOne), gives fillip to indigenous treatment of black fungus

Hyderabad based MSN Laboratories Pvt Ltd (MSN) has announced the launch of Posaconazole in India. MSN has launched the product under the brand name PosaOne as 100mg delayed-release tablets and 300 mg injections, respectively. Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients.

Many patients recovering from Covid 19 have been detected with a rare and deadly fungal infection known as mucormycosis or black fungus. With mortality rates on the incline, accessibility of anti-fungal medication is being an unmet deficit in these testing times.

Mucormycosis Histology
As an outcome of MSN’s competence in research and manufacturing of antifungal infection drugs, it is now targeting to pro-actively reach patients across India by ensuring the access of  PosaOne, through its strong distribution network and field force.

Damage caused by Mucormycosis
MSN has developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house research and development and manufacturing units. The Drug Controller General of India (DGCI) has approved this drug and it matches the international quality standards. 

As part of the Covid-19 treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg and 800mg, Oselow (Oseltamivir) as 75mg capsules and also licensed Baridoz (Baricitinib) recently with Eli Lilly. For availability of all COVID drugs from MSN, patients may contact MSN Covid Helpline - 91005 91030 or email: customercare@msnlabs.com for further assistance.

www.msnlabs.com

Comments

Popular posts from this blog

ARFF unit at Mangaluru International Airport is future ready

KIOCL Ltd Achieves Stellar Performance In Q1

Kolar Mangoes Head For Delhi In Karnataka's First Kisan Rail